Search Results

Thirty-Day TOBA Data Presented for Intact's Tack-It System

January 28, 2014—Prof.

Six-Month DISRUPT PAD Results Reported for Shockwave's Lithoplasty System

September 19, 2016—Prof.

Veryan's BioMimics 3D Stent Shows Promise in Early MIMICS Data

October 11, 2012—Principal Investigator Prof.

ILLUMENATE 12-Month Interim Data Support Spectranetics' Stellarex DCB

April 26, 2016—The Spectranetics Corporation announced that 12-month interim data from the ILLUMENATE Global Study were presented by Global Principal Investigator Prof.

Twelve-Month Results of Zilver PTX in Long Femoropopliteal Lesions Presented at LINC

January 29, 2014—At LINC 2014: The Leipzig Interventional Course in Leipzig, Germany, Prof. Thomas Zeller, MD, presented the 12-month results of a postmarket study evaluating the Zilver PTX paclitaxel-eluting stent (Cook Medical, Bloomington, IN) in long lesions.

IN.PACT DEEP Drug-Eluting Balloon Data Show No Differential Treatment Effect, Trend Toward Increased Amputation Rate in Below-the-Knee CLI Patients

January 29, 2014—New data from the IN.PACT DEEP clinical trial were presented by Prof.

Interim Results Presented for QT Vascular's Chocolate Touch

October 6, 2015—QT Vascular Ltd. announced the release of the interim results from ENDURE, the first study of the company’s Chocolate Touch peripheral drug-coated balloon to treat patients with above-the-knee peripheral artery disease.

Six-Month DISRUPT PAD Results Presented for Shockwave Medical's Lithoplasty

September 19, 2016—Shockwave Medical announced positive clinical results from the pooled DISRUPT PAD study, a single-arm, two-phase, multicenter study evaluating the safety and performance of the company’s Lithoplasty system in calcified peripheral lesions.

MIMICS-2 Study Begins for Veryan Medical's BioMimics 3D Stent System

July 1, 2015—Veryan Medical Ltd. announced the commencement of the MIMICS-2 study of the company’s BioMimics 3D stent system, which features a nitinol stent with a three-dimensional (3D) helical geometry to treat disease of the femoropopliteal artery.

MIMICS Data Presented for Veryan's BioMimics 3D Stent

October 9, 2013—Veryan Medical Ltd. (Horsham, UK) announced that the company's BioMimics 3D stent, which features a three-dimensional (3D) helical geometry, has demonstrated safety and promising clinical performance at 12 months in the treatment of patients with peripheral arterial disease (PAD) undergoing femoropopliteal artery intervention.

Full 2-Year MIMICS Data Confirm Long-Term Patency Protection With Veryan's BioMimics 3D Stent

May 30, 2014—Veryan Medical, Ltd. announced that full 2-year data from the MIMICS study were presented at the 15th annual New Cardiovascular Horizons (NCVH) conference in New Orleans, Louisiana.

Veryan Medical Announces Milestones in the MIMICS Clinical Program

June 13, 2016—Veryan Medical has announced 2-year results from the MIMICS randomized controlled trial, updated the enrollment figures for MIMICS-2, and shared details on the upcoming commencement of the MIMICS 3D registry.

DISRUPT PAD Study Results Presented for Shockwave Medical's Lithoplasty System

April 27, 2016—Shockwave Medical announced that positive clinical results from the pooled DISRUPT PAD study were presented at the 2016 Charing Cross Symposium in London, United Kingdom.

New Paclitaxel Meta-Analysis Questions Safety in CLI Population; Concerns Voiced as to Methods

January 15, 2020—In the wake of a year spent scrutinizing the finding of a mortality signal related to paclitaxel-coated balloons and stents in the superficial femoral artery (SFA), a new publication again calls the safety of paclitaxel into question, only this time in the critical limb ischemia (CLI) population.